ImageneBio, Inc. (IMA) - Total Liabilities
Based on the latest financial reports, ImageneBio, Inc. (IMA) has total liabilities worth $9.97 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ImageneBio, Inc. long-term investment allocation to see how much of total assets are deployed in long-term investments.
ImageneBio, Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how ImageneBio, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ImageneBio, Inc. (IMA) total assets.
ImageneBio, Inc. Competitors by Total Liabilities
The table below lists competitors of ImageneBio, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sajo Oyang
KO:006090
|
Korea | ₩198.54 Billion |
|
Shan-Loong Transportation Co Ltd
TW:2616
|
Taiwan | NT$5.22 Billion |
|
Eloxx Pharmaceuticals, Inc.
NASDAQ:ELOX
|
USA | $16.97 Million |
|
Falcon Machine Tools Co Ltd
TWO:4513
|
Taiwan | NT$2.94 Billion |
|
TROPHY GAMES Development AS
CO:TGAMES
|
Denmark | Dkr11.62 Million |
|
Park Elektrik Uretim Madencilik Sanayi ve Ticaret AS
IS:PRKME
|
Turkey | TL725.06 Million |
|
Snow Lake Resources Ltd
NASDAQ:LITM
|
USA | $11.14 Million |
|
Gray Television Inc
NYSE:GTN-A
|
USA | $7.56 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down ImageneBio, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ImageneBio, Inc. balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 21.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ImageneBio, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ImageneBio, Inc. (2018–2025)
The table below shows the annual total liabilities of ImageneBio, Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $19.84 Million | +27.36% |
| 2024-12-31 | $15.58 Million | -30.26% |
| 2023-12-31 | $22.34 Million | -11.68% |
| 2022-12-31 | $25.29 Million | -36.78% |
| 2021-12-31 | $40.00 Million | -85.15% |
| 2020-12-31 | $269.45 Million | +82.76% |
| 2019-12-31 | $147.44 Million | +121.66% |
| 2018-12-31 | $66.52 Million | -- |
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerl… Read more